Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate…

Source

Previous articlePT381 – DMT, Hierarchies of Complexity, and Reality Switch Technologies
Next articleOptimi Health Announces Re-Appointments to Board of Directors